Lexaria Bioscience provides GLP-1 strategic update

Lexaria Biosciencs provides the following glucagon-like peptide-1 strategic update. The company said, “Lexaria is rapidly executing its multi-faceted strategy centered around its proprietary DehydraTECH processing technology. Our main goal is to attract pharmaceutical companies seeking the benefits of adopting Lexaria’s technology for use with their own existing drug products. This first prong of our strategy has been evidenced and validated by the Company’s entry in a material transfer agreement with a pharmaceutical company which was announced in September of 2024. Lexaria continues to collaborate with its pharmaceutical partner on examining the impact of DehydraTECH processing. In the second prong of our strategy, the Company is examining the potential to develop and launch a patented DehydraTECH-CBD product within GLP-1. This could come in the form of a partnership with an existing player or Lexaria could potentially launch its own internally developed product(s). Lastly, in the third prong of our strategy, the Company is investigating the possibility of developing and selling the world’s first oral version of a leading injectable GLP-1 drug, liraglutide, using DehydraTECH. As such, GLP-1 industry developments have the potential to dramatically affect Lexaria’s strategy and future. The GLP-1 industry is experiencing revolutionary advancements across multiple healthcare sectors. If there has ever been a class of drugs that could change the world – or is perhaps already changing the world – it would be GLP-1. As tens of millions of people around the world utilize these drugs in their pursuit of better health outcomes, there will of course be unwanted side effects and even negative health outcomes in some fraction of GLP-1 drug users. With that said, the benefits of these drugs overwhelmingly outweigh all of the currently known negative outcomes.”